Two-in-One Polymeric NO-Donor Prodrugs Mediate Precision and Synergistic Prostate Cancer Treatment
ACS Applied Materials & Interfaces · 2023
DOI: 10.1021/acsami.3c04167 ↗At a glance
Journal article in ACS Applied Materials & Interfaces, 2023. Written by Bingbing Zhao and 9 co-authors. Institution: Department of Pharmaceutical Engineering, China Pharmaceutical University, Nanjing 211198, China. Major MEDLINE topics: Prostatic Neoplasms, Castration-Resistant, Prodrugs. Cited 12 times so far (Crossref); 49 references. Funded by: National Natural Science Foundation of China, Jiangsu Agriculture Science and Technology Innovation Fund.
Abstract (original language)
Chemotherapy predominates in clinical treatment of prostate cancer (PCa), while irreversible resistance to chemotherapeutics and severe side effects hinder the therapeutic efficacy, especially in castration-resistant PCa (CRPC). Herein, a bombesin (BBN)-decorated two-in-one prodrug (T-NO/E2-PMs) incorporating a polymeric nitric oxide (NO) donor and acetal-linked 17β-estradiol (E2) in one backbone is developed, aiming to inhibit androgen receptor (AR) expression, reprogram the tumor microenvironment of CRPC, and enhance estradiol-mediated hypoxic CRPC therapy. Following efficient internalization mediated by BBN, T-NO/E2-PMs releases estradiol and NO in response to the unique intracellular environments. Both in vitro and in vivo studies demonstrate that the T-NO/E2-PMs nano-prodrug along with NO release potently downregulates AR levels to reverse CRPC and further enhances the chemo-sensitization of estradiol to PCa PC-3 cell apoptosis and the inhibition of metastasis. Collectively, this two-in-one nano-prodrug strategy offers a promising platform for construction of advanced nanomedicine to boost the therapeutic efficacy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmaceutical Engineering, China Pharmaceutical University, Nanjing 211198, China.
- Engineering Research Center for Smart Pharmaceutical Manufacturing Technologies, Ministry of Education, School of Engineering, China Pharmaceutical University, Nanjing 211198, China.
ORCID profiles: Wei Chen, Yinan Zhong, Hongliang Qian
Funding
- National Natural Science Foundation of China
- Jiangsu Agriculture Science and Technology Innovation Fund
Cite
APA
Zhao, B., Wan, Y., Zhou, X., Zhang, J., Chen, J., Yang, J., Liu, Y., Chen, W., Zhong, Y., & Qian, H. (2023). Two-in-One Polymeric NO-Donor Prodrugs Mediate Precision and Synergistic Prostate Cancer Treatment. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.3c04167
Vancouver
Zhao B, Wan Y, Zhou X, Zhang J, Chen J, Yang J, et al. Two-in-One Polymeric NO-Donor Prodrugs Mediate Precision and Synergistic Prostate Cancer Treatment. ACS Applied Materials & Interfaces. 2023. doi:10.1021/acsami.3c04167
BibTeX
@article{Zhao2023,
author = {Zhao, Bingbing and Wan, Yuqing and Zhou, Xiang and Zhang, Junmei and Chen, Jiaxin and Yang, Jiachen and Liu, Yunzhu and Chen, Wei and Zhong, Yinan and Qian, Hongliang},
title = {Two-in-One Polymeric NO-Donor Prodrugs Mediate Precision and Synergistic Prostate Cancer Treatment},
journal = {ACS Applied Materials & Interfaces},
year = {2023},
doi = {10.1021/acsami.3c04167}
}
EUVIMED